BioSpace News Archive

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual and special meeting of shareholders held earlier today.

Dewpoint Therapeutics, Inc. today announced biomolecular scientist Anthony (Tony) Hyman was awarded the 2023 Breakthrough Prize in Life Sciences for discovering a new mechanism of cellular organization mediated by phase separation of proteins and RNA into membraneless liquid droplets called condensates.

Aadi Bioscience, Inc. announced it has entered into a securities purchase agreement with a new accredited investor and certain existing investors to issue and sell an aggregate of 3,373,526 shares of its common stock at a price of $12.50 per share.

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip’ral platform to augment therapeutics through effective oral delivery by developing differentiated products relative to standard of care, announced today that it will present at the Ladenburg Thalmann 2022 Healthcare Conference on September 29 in New York.

Titan Medical Inc. announced the publication of international patent application No. PCT/CA2022/050392, which the company anticipates pursuing in the United States and other key markets under the Patent Cooperation Treaty.

Precision Optics Corporation, Inc. (OTCQB: PEYE) (the “Company”) today announced that it has scheduled a conference call to discuss its fiscal year 2022 financial results on Tuesday, September 27, 2022, at 5:00pm ET.

NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results for half-year ending June 30, 2022, on Wednesday, September 28, 2022, after the close of the US market.

Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”) today announced that it will effect a 1-for-15 reverse split of its common stock, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 23, 2022, and also provided a regulatory update related to its intravenous (“IV”) Tramadol product candidate.

Scholar Rock, a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role announced that the company granted equity awards as a material inducement to an employee hired by Scholar Rock in September 2022.

Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.